HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia < 60 Years

This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer. Donor cellular therapy is a short-term transfusion of cells from a family member who is incompletely matched. The use of these partially matched white blood cells may help improve response to standard chemotherapy (cytarabine) and reduce some of the risks of infection, without a permanent transplant. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving donor cellular therapy after cytarabine may kill more cancer cells.

开始日期2018-12-12

申办/合作机构

University of Southern California

[+1]

NCT01871441 / Terminated临床2期IIT

A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes

This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant works in treating patients with hematologic malignancies. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Giving an infusion of the donor's T cells (donor lymphocyte infusion) may replace the patient's immune cells and help destroy any remaining cancer cells. When the stem cells from a related donor, that closely matches the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

开始日期2013-05-17

申办/合作机构

Sidney Kimmel Cancer Center at Thomas Jefferson University

NCT01839916 / Completed临床2期IIT

Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies

This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies. In a donor stem cell transplant, the donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.

开始日期2013-04-04

申办/合作机构

The University of Chicago

[+1]

100 项与 Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University) 相关的专利（医药）

登录后查看更多信息

100 项与 Allogeneic lymphocytes(Sidney Kimmel Cancer Center at Thomas Jefferson University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
淋巴母细胞淋巴瘤	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
成人T细胞白血病/淋巴瘤	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
加速期慢性骨髄性白血病	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
间变性大细胞淋巴瘤	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
难治性贫血伴原始细胞过多	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
急性转化期慢性粒细胞性白血病	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
伯基特淋巴瘤	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
慢性淋巴细胞白血病	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24
慢性粒单核细胞白血病	临床2期	美国	Sidney Kimmel Cancer Center at Thomas Jefferson University	2012-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01839916 (CTgov)	临床2期	复发性边缘区淋巴瘤 \| 复发性成人III级淋巴肉芽肿 \| 伯基特淋巴瘤 ... 更多	77	laboratory biomarker analysis+therapeutic allogeneic lymphocytes	衊鬱醖鑰襯窪選選網顧(蓋鏇齋選餘鏇網夢製積) = 鑰壓選鏇遞淵蓋築選顧蓋餘壓製襯餘製鹹繭醖 (齋窪窪廠鏇膚餘選醖艱, 築蓋鏇蓋構鹹淵遞淵蓋 ~ 衊簾範襯選鑰鹽壓夢獵) 更多	-	2019-08-07
NCT01871441 (CTgov)	临床2期	血液肿瘤	4	Allogeneic hematopoietic stem cell transplantation (HSCT)+Cyclophosphamide+Donor lymphocytes infusion (DLI)+Tacrolimus+mycophenolate mofetil	觸鹹衊網衊製鏇艱鹽製(築糧蓋淵鏇憲繭範顧鬱) = 築糧鹹艱糧範鹽鹽顧觸築範壓願選鹹衊齋網觸 (夢淵窪襯窪鏇齋選廠艱, 餘簾襯積鏇壓製鏇淵窪 ~ 製膚築衊夢築襯鏇衊築) 更多	-	2018-01-09
NCT00245037 (CTgov)	临床1/2期	骨髓增生异常/骨髓增生性疾病 \| 多发性骨髓瘤 \| 骨髓增生性疾病 ... 更多	147	peripheral blood stem cell transplantation+cyclosporine+fludarabine phosphate+Busulfan+therapeutic allogeneic lymphocytes+mycophenolate mofetil+methotrexate+Phenytoin	範觸顧製製醖繭壓壓簾(蓋蓋窪範廠淵衊餘廠蓋) = 選鏇夢積夢襯廠鏇窪鬱構糧襯遞鏇蓋膚選醖蓋 (觸齋選獵衊選願繭壓築, 壓壓憲範鏇選鹽築觸網 ~ 簾獵鏇膚遞獵網鹽構鬱) 更多	-	2017-07-02
NCT01118013 (CTgov)	临床2期	骨髓增生异常/骨髓增生性疾病 \| 浆细胞肿瘤 \| 多发性骨髓瘤 ... 更多	6	allogeneic hematopoietic stem cell transplantation+fludarabine phosphate+Busulfan+therapeutic allogeneic lymphocytes+Filgrastim+Tacrolimus+mycophenolate mofetil+Methotrexate	廠淵鏇鹽獵願鹹鹹蓋鏇(築窪遞糧簾淵夢鏇築鏇) = 繭餘糧鑰衊積鏇鹽獵憲製鏇製築顧範蓋窪窪膚 (觸鑰窪鹹膚蓋鏇壓餘鬱, 積醖齋襯醖築醖積築憲 ~ 範鏇廠憲膚獵淵鏇鏇繭) 更多	-	2017-03-24
NCT00068718 (CTgov)	临床1/2期	复发性浆细胞骨髓瘤 \| 急性髓性白血病 \| 复发性成人急性淋巴细胞白血病 ... 更多	35	Therapeutic Allogeneic Lymphocytes	鹽簾襯選艱選淵齋構憲(範齋衊糧遞艱獵遞憲鑰) = 夢齋構齋範憲簾鏇鏇齋鹽選鏇築憲鏇廠鬱襯襯 (鹽艱鑰遞顧鹹觸鏇艱鏇, 觸選簾膚蓋窪鬱壓網艱 ~ 糧壓鹽網夢蓋艱網鬱糧) 更多	-	2017-03-10
NCT00074269 (CTgov)	临床2期	转移性乳腺癌	5	Anti-Thymocyte Globulin+cyclosporine+fludarabine phosphate+therapeutic allogeneic lymphocytes+melphalan+Filgrastim+methotrexate	鑰獵獵築獵壓醖襯鹹衊(窪淵積製鹹艱顧選艱糧) = 齋簾積鹹糧醖範積願鹹憲夢淵襯鹽觸鑰蓋壓網 (遞醖網築製齋糧鏇鹽鏇, 膚廠廠簾廠繭艱蓋窪糧 ~ 鏇窪醖範鑰鬱獵觸積醖) 更多	-	2014-11-24
NCT00176501 (CTgov)	临床2期	肾细胞癌	3	therapeutic allogeneic lymphocytes	鑰積膚淵製廠蓋襯壓壓(鏇簾憲簾齋壓淵餘遞餘) = 積餘獵壓鹽醖願淵顧製構遞鑰襯鬱憲衊壓鹹鏇 (醖壓觸獵鏇網鏇鏇網積, 願窪網壓襯築構糧遞襯 ~ 構夢構餘齋簾廠膚簾遞) 更多	-	2014-01-06